E Therapeutics (ETX)
ETX Share PerformanceMore
|52 week high||27.5000 17/12/15|
|52 week low||8.3000 24/11/16|
|52 week change||-17.1250 (-67.16%)|
|4 week volume||720,053 09/11/16|
Latest News« previous» nextMore
23/11/2016 - 16:21 RNS
RNS Number: 9836P e-Therapeutics plc 23 November 2016 23 November 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Grant of share options and Directors' dealings Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total o...
06/10/2016 - 09:25 StockMarketWire
Prof Trevor Jones, Non Executive Director, bought 41,204 shares in the company on the 5th October 2016 at a price of 11.33p...
06/10/2016 - 09:12 RNS
RNS Number: 8817L e-Therapeutics plc 06 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Directors' Dealings and Issue of Equity Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that o n 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,20...
03/10/2016 - 13:03 RNS
RNS Number: 5273L e-Therapeutics plc 03 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Further re: Directors' Shareholdings 3 October 2016, Oxford and Newcastle, UK: Further to e-Therapeutics' announcement on 21 September 2016, the Company announces the following additional detail on the increase to Sean Nicolson's shareholding in the Com...
21/09/2016 - 15:06 RNS
Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue
20/09/2016 - 06:27 StockMarketWire
e-Therapeutics posts an operating loss of 9.7m for the six months to the end of July (HY15: loss of 5.9m), including 2.1m good...
20/09/2016 - 06:00 RNS
Announcement of half-year/second quarter financial results
14/09/2016 - 11:08 RNS
Miscellaneous medium priority announcements
|Dividend yield||0 %|
Equity Research (ETX)
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19....
e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and...
e-Therapeutics’ (ETX) share price fell c 30% on news that the ETS6103 Phase IIb trial as a second-line therapy for major depressive disorder (MDD) failed to meet its primary efficacy endpoint....
- 1 of 3
Latest discussion posts More
“RNS available at company's website. although seems to be missing in III ...”▼
“RNS out today afternoon. Good operational progress. Not sure if that warrants a steep rise in SP as seen over the last few days, including a further 15% today. But I ...”▼
“Clearly somebody knows something we don't. Would that be called insider trading I wonder.”▼
Codes & Symbols
|Symbols||ETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX|